Insulet | PODD - Ebitda

Stock Price
251.30
Daily Change
-5.32 -2.07%
Monthly
-11.36%
Yearly
-9.76%
Q1 Forecast
247.93

Insulet reported $160M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Abbott USD 3.09B 44M Sep/2025
Align Technology USD 203.61M 66M Jun/2025
AtriCure USD 17.8M 2.45M Sep/2025
Avanos Medical USD -63.9M 85.5M Jun/2025
Baxter International USD 462M 137M Jun/2025
Becton, Dickinson and Co. USD 2.15B 674M Sep/2025
Boston Scientific USD 1.37B 9M Jun/2025
Cardinal Health USD 986M 319M Sep/2025
Cooper Companies USD 336.6M 14.8M Sep/2025
Dexcom USD 368.4M 59.6M Sep/2025
Edwards Lifesciences USD 469M 57.7M Jun/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
Globus Medical USD 252.6M 43.92M Sep/2025
ICU Medical USD 100.31M 36.51M Jun/2025
Insulet USD 160M 2.5M Sep/2025
Integra LifeSciences USD 78.45M 550.67M Sep/2025
J&J USD 9.52B 389M Sep/2025
Masimo USD 72M 42.6M Jun/2025
Medtronic USD 2.44B 139M Sep/2025
Merit Medical Systems USD 83.96M 10.65M Jun/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Solventum Corp USD 475M 176M Sep/2025
Stryker USD 1.67B 206M Sep/2025
Tandem Diabetes Care USD 2.77M 4.62M Sep/2025
Teleflex USD 207.62M 15.28M Jun/2025
West Pharmaceutical Services USD 213.1M 14.6M Sep/2025
Zimmer Biomet Holdings USD 575.7M 26.1M Jun/2025